Free Trial
→ The gold strategy that works whether prices rise or fall (From Brownstone Research) (Ad)tc pixel Free AREC Stock Alerts

Arecor Therapeutics (AREC) Competitors

Arecor Therapeutics logo
GBX 68.15 +2.15 (+3.26%)
As of 05/15/2026 08:25 AM Eastern
Compare

AREC vs. MPH, BVXP, FARN, 4BB, and ORPH

Should you buy Arecor Therapeutics stock or one of its competitors? MarketBeat compares Arecor Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arecor Therapeutics include Mereo BioPharma Group plc (MPH.L) (MPH), Bioventix (BVXP), Faron Pharmaceuticals Oy (FARN), 4basebio (4BB), and Open Orphan (ORPH). These companies are all part of the "biotechnology" industry.

How does Arecor Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Mereo BioPharma Group plc (MPH.L) has higher earnings, but lower revenue than Arecor Therapeutics. Mereo BioPharma Group plc (MPH.L) is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A
Arecor Therapeutics£1.71M15.01-£10.68M£2.0034.08

Arecor Therapeutics has a net margin of 38.74% compared to Mereo BioPharma Group plc (MPH.L)'s net margin of 0.00%. Arecor Therapeutics' return on equity of 14.26% beat Mereo BioPharma Group plc (MPH.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma Group plc (MPH.L)N/A N/A N/A
Arecor Therapeutics 38.74%14.26%-37.31%

In the previous week, Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled Arecor Therapeutics'average media sentiment score.

Company Overall Sentiment
Mereo BioPharma Group plc (MPH.L) Neutral
Arecor Therapeutics Neutral

6.0% of Arecor Therapeutics shares are held by institutional investors. 4.8% of Arecor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Arecor Therapeutics beats Mereo BioPharma Group plc (MPH.L) on 7 of the 8 factors compared between the two stocks.

How does Arecor Therapeutics compare to Bioventix?

Bioventix (LON:BVXP) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Bioventix has higher revenue and earnings than Arecor Therapeutics. Bioventix is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.54M7.08£8.12M£140.5212.10
Arecor Therapeutics£1.71M15.01-£10.68M£2.0034.08

Bioventix has a beta of 0.484, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Arecor Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market.

Bioventix has a net margin of 59.30% compared to Arecor Therapeutics' net margin of 38.74%. Bioventix's return on equity of 65.83% beat Arecor Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix59.30% 65.83% 54.07%
Arecor Therapeutics 38.74%14.26%-37.31%

In the previous week, Bioventix had 1 more articles in the media than Arecor Therapeutics. MarketBeat recorded 1 mentions for Bioventix and 0 mentions for Arecor Therapeutics. Bioventix's average media sentiment score of 0.00 equaled Arecor Therapeutics'average media sentiment score.

Company Overall Sentiment
Bioventix Neutral
Arecor Therapeutics Neutral

21.1% of Bioventix shares are held by institutional investors. Comparatively, 6.0% of Arecor Therapeutics shares are held by institutional investors. 6.2% of Bioventix shares are held by insiders. Comparatively, 4.8% of Arecor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Bioventix beats Arecor Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Arecor Therapeutics compare to Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy (LON:FARN) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Faron Pharmaceuticals Oy has a beta of 1.109, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Arecor Therapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the broader market.

Arecor Therapeutics has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A
Arecor Therapeutics£1.71M15.01-£10.68M£2.0034.08

1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 6.0% of Arecor Therapeutics shares are held by institutional investors. 3.9% of Faron Pharmaceuticals Oy shares are held by company insiders. Comparatively, 4.8% of Arecor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Arecor Therapeutics has a net margin of 38.74% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat Arecor Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 45.13% -70.00%
Arecor Therapeutics 38.74%14.26%-37.31%

In the previous week, Faron Pharmaceuticals Oy's average media sentiment score of 0.00 equaled Arecor Therapeutics'average media sentiment score.

Company Overall Sentiment
Faron Pharmaceuticals Oy Neutral
Arecor Therapeutics Neutral

Summary

Arecor Therapeutics beats Faron Pharmaceuticals Oy on 8 of the 10 factors compared between the two stocks.

How does Arecor Therapeutics compare to 4basebio?

Arecor Therapeutics (LON:AREC) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

In the previous week, 4basebio had 4 more articles in the media than Arecor Therapeutics. MarketBeat recorded 4 mentions for 4basebio and 0 mentions for Arecor Therapeutics. 4basebio's average media sentiment score of 0.33 beat Arecor Therapeutics' score of 0.00 indicating that 4basebio is being referred to more favorably in the news media.

Company Overall Sentiment
Arecor Therapeutics Neutral
4basebio Neutral

Arecor Therapeutics has a beta of -0.18, meaning that its share price is 118% less volatile than the broader market. Comparatively, 4basebio has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

4basebio has a consensus price target of GBX 1,600, indicating a potential upside of 280.95%. Given 4basebio's stronger consensus rating and higher possible upside, analysts plainly believe 4basebio is more favorable than Arecor Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arecor Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

4basebio has higher revenue and earnings than Arecor Therapeutics. 4basebio is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arecor Therapeutics£1.71M15.01-£10.68M£2.0034.08
4basebio£1.78M36.56-£9.84M-£99.00N/A

6.0% of Arecor Therapeutics shares are held by institutional investors. Comparatively, 0.9% of 4basebio shares are held by institutional investors. 4.8% of Arecor Therapeutics shares are held by company insiders. Comparatively, 12.1% of 4basebio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Arecor Therapeutics has a net margin of 38.74% compared to 4basebio's net margin of 0.00%. Arecor Therapeutics' return on equity of 14.26% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
Arecor Therapeutics38.74% 14.26% -37.31%
4basebio N/A -231.29%-54.30%

Summary

4basebio beats Arecor Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Arecor Therapeutics compare to Open Orphan?

Arecor Therapeutics (LON:AREC) and Open Orphan (LON:ORPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Open Orphan has higher revenue and earnings than Arecor Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arecor Therapeutics£1.71M15.01-£10.68M£2.0034.08
Open Orphan£34.71M0.00N/AN/AN/A

Arecor Therapeutics has a net margin of 38.74% compared to Open Orphan's net margin of 0.00%. Arecor Therapeutics' return on equity of 14.26% beat Open Orphan's return on equity.

Company Net Margins Return on Equity Return on Assets
Arecor Therapeutics38.74% 14.26% -37.31%
Open Orphan N/A N/A N/A

In the previous week, Arecor Therapeutics' average media sentiment score of 0.00 equaled Open Orphan'saverage media sentiment score.

Company Overall Sentiment
Arecor Therapeutics Neutral
Open Orphan Neutral

6.0% of Arecor Therapeutics shares are held by institutional investors. 4.8% of Arecor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Arecor Therapeutics beats Open Orphan on 5 of the 7 factors compared between the two stocks.

Get Arecor Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AREC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AREC vs. The Competition

Export
MetricArecor TherapeuticsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£25.73M£467.15M£6.33B£2.74B
Dividend YieldN/A3.86%2.80%6.07%
P/E Ratio34.083.8820.07365.91
Price / Sales15.017,763.50551.3288,019.88
Price / Cash5.0713.1343.0427.89
Price / Book4.1184.219.837.74
Net Income-£10.68M-£96.07M£3.56B£5.89B
7 Day Performance-1.05%0.89%0.25%0.30%
1 Month Performance3.97%0.44%-1.30%1.57%
1 Year Performance65.82%68.68%33.61%85.84%

Arecor Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AREC
Arecor Therapeutics
N/AGBX 68.15
+3.3%		N/A+67.6%£25.73M£1.71M34.0810
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50
BVXP
Bioventix
N/AGBX 1,677
-1.4%		N/A-40.1%£87.62M£12.54M11.9312
FARN
Faron Pharmaceuticals Oy
N/AGBX 42
+1.2%		N/A-80.1%£83.80MN/AN/A34
4BB
4basebio
1.6669 of 5 stars		GBX 439.50
-3.4%		GBX 1,600
+264.1%		-63.2%£68.06M£1.78MN/A101

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:AREC) was last updated on 5/16/2026 by MarketBeat.com Staff.
From Our Partners
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Secret behind near perfectly timed stock trades…?
After 20 years of professional trading, Ross Givens says this is the single most lucrative market strategy he ...
Traders Agency | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
The NASTY TRUTH about the SpaceX IPO
In nearly every major IPO, roughly 95% of the gains are captured before retail investors can place a trade. It...
The Oxford Club | Sponsoredtc pixel